Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
Vaccine
; 26(50): 6373-82, 2008 Nov 25.
Article
em En
| MEDLINE
| ID: mdl-18822334
ABSTRACT
MEDI-534 is a bivalent live attenuated vaccine candidate against human respiratory syncytial virus (hRSV) and human parainfluenza virus type 3 (hPIV3) that was previously shown to be immunogenic and to protect rodents and African green monkeys from wild-type (wt) hRSV challenge. We performed further preclinical evaluations to address the safety of MEDI-534 prior to human testing. MEDI-534 did not predispose rodents to enhanced RSV disease following wt-RSV challenge, and the tissue tropism of the chimeric virus was confined to the respiratory tract. Representative clinical trial material did not produce toxicity in rats. In adults, MEDI-534 was highly restricted in replication, did not boost RSV and PIV3 antibody titers, and produced no medically significant vaccine-related adverse events thereby warranting further evaluation in pediatric populations.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por Respirovirus
/
Vacinas Atenuadas
/
Infecções por Vírus Respiratório Sincicial
/
Vírus da Parainfluenza 3 Humana
/
Vacinas contra Parainfluenza
/
Vacinas contra Vírus Sincicial Respiratório
Tipo de estudo:
Clinical_trials
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Estados Unidos